Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.

Schittenhelm J1,2, Krischker N2, Gepfner-Tuma I1,3, Behling F1,4, Noell S1,4, Eckert F1,5,6, Biskup S7, Tabatabai G1,3,8,6.
  1. Center for CNS Tumors, Comprehensive Cancer Center Tuebingen-Stuttgart, University Hospital of Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
  2. Department of Neuropathology, Institute of Pathology and Neuropathology, University Hospital of Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
  3. Interdisciplinary Division of Neurooncology, Departments of Vascular Neurology & Neurosurgery University Hospital of Tuebingen, Eberhard Karls University of Tuebingen, Hertie-Institute for Clinical Brain Research, Tuebingen, Germany.
  4. Department of Neurosurgery, University Hospital of Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
  5. Department of Radiation Oncology, University Hospital of Tuebingen, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
  6. German Consortium for Translational Cancer Research (DKTK), DKFZ partner site Tuebingen, Tuebingen, Germany.
  7. CeGaT GmbH and Praxis für Humangenetik Tuebingen, Tuebingen, Germany.
  8. Center for Personalized Medicine, Eberhard Karls University of Tuebingen, Tuebingen, Germany.